| Literature DB >> 35168192 |
Anna Nowicka1,2, Jakub Jaszczak2, Anna Szymanek Pasternak1,3, Krzysztof Simon1,3.
Abstract
BACKGROUND: The COVID-19 pandemic has sped up the implementation of telehealth solutions in medicine. A few symptom checkers dedicated for COVID-19 have been described, but it remains unclear whether and how they can affect patients and health systems.Entities:
Keywords: COVID-19; COVID-19 remote triage; COVID-19 self-assessment; online applications; preclinical triage; self-assessment tool; symptom checker
Year: 2022 PMID: 35168192 PMCID: PMC8982648 DOI: 10.2196/34134
Source DB: PubMed Journal: JMIR Hum Factors ISSN: 2292-9495
Figure 1Finished CRA interviews daily (blue line); for comparison, daily number of new diagnosed COVID-19 cases in Poland (red line). CRA: COVID-19 risk assessment.
Figure 2Age and sex distribution of admission room patients (N=291).
Figure 3Age and sex distribution of CRA users. CRA: COVID-19 risk assessment.
Distribution of CRAa interview outcomes (N=248,862).
| Triage | Patients, n (%) |
| Asymptomatic | 98,081 (39.41) |
| Non-COVID-19, nonserious | 73,145 (29.39) |
| COVID-19 suspected, serious | 30,494 (12.25) |
| Non-COVID-19, serious | 21,980 (8.83) |
| Quarantine | 15,649 (6.29) |
| COVID-19 suspected, nonserious | 9513 (3.82) |
aCRA: COVID-19 risk assessment.
Distribution of CRAa interview outcomes: matrix of the clinical suspicion of COVID-19 (N=248,862).
| Severity of presented symptoms | COVID-19 suspected, n (%) | Non-COVID-19, n (%) |
| Serious | 30,494 (12.25) | 21,980 (8.83) |
| Nonserious | 9513 (3.82) | 171,226 (68.80) |
aCRA: COVID-19 risk assessment.
Distribution of comorbiditiesa in the CRAb tool and admission room groups.
| Comorbidities | CRA tool | Admission room | |||||
|
| COVID-19 positive (N=40,007), n (%) | COVID-19 negative (N=193,206), n (%) | COVID-19 positive (N=232), n (%) | COVID-19 negative (N=59), n (%) | |||
| Cardiovascular diseases | 9346 (23.36) | 26,296 (13.61) | <.001 | 125 (53.88) | 13 (22.03) | <.001 | |
| Diabetes | 1680 (4.20) | 4012 (2.08) | <.001 | 51 (21.98) | 5 (8.47) | .02 | |
| Current cancer | 818 (2.04) | 1517 (0.79) | <.001 | 28 (12.07) | 2 (3.39) | .06 | |
| Diagnosed chronic lung disease | 2461 (6.15) | 5425 (2.81) | <.001 | 20 (8.62) | 2 (3.39) | .27 | |
| History of chronic liver disease | 1064 (2.66) | 2140 (1.11) | <.001 | 7 (3.02) | 1 (1.69) | .99 | |
| History of chronic kidney disease | 967 (2.42) | 1851 (0.96) | <.001 | 7 (3.02) | 1 (1.69) | .99 | |
| Weakened immune system | 4309 (10.77) | 9629 (4.98) | <.001 | 5 (2.16) | 0 | 0.59 | |
aOverall comorbidities: There were 20,645 comorbidities in COVID-19 positives and 50,870 comorbidities in COVID-19 negatives in the CRA tool group. There were 243 comorbidities in COVID-19 positives and 24 comorbidities in COVID-19 negatives in the admission room group.
bCRA: COVID-19 risk assessment.
cP values for CRA: test of proportions.
dP values for the admission room: Fisher exact test.
Symptom and risk factor distribution of CRAa tool users and admission room patients.
| Symptom or risk factor | CRA tool | Admission room | |||
|
| COVID-19 positive (N=40,007), n (%) | COVID-19 negative (N=193,206), n (%) | COVID-19 positive (N=232), n (%) | COVID-19 negative (N=59), n (%) | |
| Cough | 25,062 (62.64) | 29,521 (15.28) | 138 (59.48) | 30 (50.85) | |
| Fever | 23,123 (57.80) | 20,292 (10.50) | 146 (62.93) | 29 (49.15) | |
| Symptoms getting worse quickly | 19,816 (49.53) | 0 | N/Ab | N/A | |
| Shortness of breath | 15,157 (37.89) | 12,717 (6.58) | 87 (37.50) | 27 (45.76) | |
| Faster breathing | 12,964 (32.40) | 0 | N/A | N/A | |
| Fatigue | 5987 (14.96) | 52,630 (27.24) | 40 (17.24) | 19 (32.20) | |
| Headache | 4497 (11.24) | 38,115 (19.73) | 19 (8.19) | 4 (6.78) | |
| Sore throat | 3975 (9.94) | 35,645 (18.45) | 17 (7.33) | 9 (15.25) | |
| Muscle pain | 3351 (8.38) | 27,015 (13.98) | 42 (18.10) | 17 (28.81) | |
| Coughing up blood | 2006 (5.01) | 0 | 1 (0.43) | 0 | |
| Chills | 1906 (4.76) | 13,740 (7.11) | 2 (0.86) | 2 (3.39) | |
| Diarrhea | 1242 (3.10) | 14,109 (7.30) | 35 (15.09) | 4 (6.78) | |
| Contact with infected person | 1005 (2.51) | 0 | 166 (71.55) | 5 (8.47) | |
| Nasal catarrh | 954 (2.38) | 6134 (3.17) | 20 (8.62) | 5 (8.47) | |
| Loss of smell or taste | 947 (2.37) | 6034 (3.12) | 39 (16.81) | 2 (3.39) | |
| Nausea | 911 (2.28) | 10,599 (5.49) | 10 (4.31) | 3 (5.08) | |
| No contact with infected person | 0 | 193,206 (100) | 66 (28.45) | 54 (91.53) | |
aCRA: COVID-19 risk assessment.
bN/A: not applicable.